Journal of Clinical Pediatrics >
Clinical and genetic analysis of children with 3-hydroxy-3-methyglutaryl-coenzyme A lyase deficiency
Received date: 2022-05-05
Online published: 2023-04-07
Objective To analyze the clinical characteristics and gene variation for children with 3-hydroxy-3-methyglutaryl-coenzyme A lyase deficiency (HMGCLD). Methods The clinical data and genetic sequencing results of children with HMGCLD were analyzed. Results There were 6 patients (3 boys and 3 girls). One patient had a positive family history. Neonatal screening in the local hospital indicated HMGCLD in 3 patients, 2 patients were clinically diagnosed after the onset of the disease, and 1 patient remained disease-free. The onset age of 5 patients ranged from 10 days to 5 years and the age of first diagnosis ranged from 1 month to 7 years. There were metabolic crisis, hypoglycemia and hyperlactatemia in different degrees at the onset of the disease. Two patients died. Blood tandem mass spectrometry showed an increase in 3-hydroxyisovaleryl carnitine (C5-OH), and some of the children were accompanied by an increase in hexanedioyl carnitine (C6DC). Urine organic acid analysis showed that 3-hydroxy-3-methylglutaric acid increased significantly, along with 3-methylpentene acid and 3-hydroxyisovaleric acid. The HMGCL gene variation was found in 4 patients. Two patients had a homozygous variation of c.122G>A (p.R41Q), 1 patient had a homozygous variation of c.697C>T (p.H233Y) and 1 patient had a complex heterozygous variation of c.145-2A>G and c.590G>A (p.C197Y). Among them, c.697C>T (p.H233Y), c.145-2A>G, and c.590G>A (p.C197Y) were all reported for the first time. Protein structure was predicted to be potentially harmful, and the grade of ACMG was likely pathogenic. The other two children did not undergo genetic testing. Conclusions The clinical phenotype of HMGCLD is diverse, which can be confirmed by combining blood tandem mass spectrometry, urine organic acid analysis and gene diagnosis. Screening of HMGCLD is helpful for early diagnosis and reasonable treatment.
Guoying CHANG , Shiying LING , Wenjuan QIU , Huiwen ZHANG , Lili LIANG , Xuefan GU , Lianshu HAN . Clinical and genetic analysis of children with 3-hydroxy-3-methyglutaryl-coenzyme A lyase deficiency[J]. Journal of Clinical Pediatrics, 2023 , 41(4) : 278 -283 . DOI: 10.12372/jcp.2023.22e0624
[1] | Grünert SC, Sass JO. 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: one disease - many faces[J]. Orphanet J Rare Dis, 2020, 15(1): 48. |
[2] | Aoyama Y, Yamamoto T, Sakaguchi N, et al. Application of multiplex ligation-dependent probe amplification, and identification of a heterozygous Alu-associated deletion and a uniparental disomy of chromosome 1 in two patients with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency[J]. Int J Mol Med, 2015, 35(6): 1554-1560. |
[3] | Faull KF, Bolton PD, Halpern B, et al. The urinary organic acid profile associated with 3-hydroxy-3-methylglutaric aciduria[J]. Clin Chim Acta, 1976, 73(3): 553-559. |
[4] | 吴莫龄, 刘丽, 周知子, 等. 3-羟基-3-甲基戊二酸尿症1例的临床特点及遗传学研究[J]. 中华实用儿科临床杂志, 2017, 32(20): 1584-1586. |
[5] | 艾力克木·阿不都玩克, 古力米热·布然江, 李溪远, 等. 3-羟基-3-甲基戊二酸尿症患儿的临床诊治及3-羟基-3-甲基戊二酰裂解酶基因新突变分析[J]. 中华妇幼临床医学杂志(电子版), 2016, 1: 71-75. |
[6] | 马艳艳, 宋金青, 吴桐菲, 等. 迟发型3-羟基-3-甲基戊二酸尿症导致脑自质病[J]. 中国当代儿科杂志, 2011, 13(5): 392-395. |
[7] | 董睿, 张光业, 张开慧, 等. 一例3-羟基-3-甲基戊二酰辅酶A裂解酶缺乏症的临床与遗传学分析[J]. 中华医学遗传学杂志, 2020, 37(5): 597- 598. |
[8] | Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. |
[9] | Yang L, Yin H, Yang R, et al. Diagnosis, treatment and outcome of glutaric aciduria type I in Zhejiang province[J]. China, Med Sci Monit, 2011, 17(7): PH55-59. |
[10] | Jiang M, Liu L, Mei H, et al. Detection of inborn errors of metabolism using GC-MS: over 3 years of experience in southern China[J]. J Pediatr Endocrinol Metab, 2015, 28(3-4): 375-380. |
[11] | Leipnitz G, Vargas CR, Wajner M, et al. Disturbance of redox homeostasis as a contributing underlying pathomechanism of brain and liver alterations in 3-hydroxy-3-methylglutaryl-CoA lyase deficiency[J]. J Inherit Metab Dis, 2015, 38(6): 1021-1028. |
[12] | Park KC, Krywawych S, Richard E, et al. Cardiac complications of propionic and other inherited organic acidemias[J]. Front Cardiovasc Med, 2020, 7: 617451. |
[13] | Alfadhel M, Abadel B, Almaghthawi H, et al. HMG-CoA lyase deficiency: a retrospective study of 62 saudi patients[J]. Front Genet, 2022, 13: 88046. |
[14] | Lin WD, Wang CH, Lai CC, et al. Molecular analysis of Taiwanese patients with 3-hydroxy-3-methylglutaryl CoA lyase deficiency[J]. Clin Chim Acta, 2009, 401(1-2): 33-36. |
[15] | Grünert SC, Schlatter SM, Schmitt RN, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: Clinical presentation and outcome in a series of 37 patients[J]. Mol Genet Metab, 2017, 121(3): 206-215. |
[16] | Sulaiman RA, Al-Nemer M, Khan R, et al. Successful management of pregnancies in patients with inherited disorders of ketone body metabolism[J]. JIMD Rep, 2018, 38: 41-44. |
[17] | Mu?oz-Bonet JI, Ortega-Sánchez MD, León Guijarro JL, et al. Management and long-term evolution of a patient with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency[J]. Ital J Pediatr, 2017, 43(1): 12. |
[18] | Ferreira GC, McKenna MC. L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain[J]. Neurochem Res, 2017, 42(6): 1661-1675. |
[19] | Jones KJ, Wilcken B, Kilham H. The long-term evolution of a case of 3-hydroxy-3-methylglutaryl-coenzyme A lyase defciency associated with deafness and retinitis pigmentosa[J]. J Inherit Metab Dis, 1997, 20(6): 833-834. |
/
〈 |
|
〉 |